# Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)

> **NCT03997929** · — · COMPLETED · sponsor: **Central Hospital, Nancy, France** · enrollment: 200 (actual)

## Conditions studied

- Intra Abdominal Infections
- Candidiasis, Invasive
- Peritoneal Candidiasis
- Critically Ill

## Interventions

- **DIAGNOSTIC_TEST:** 1.3 BETA D GLUCAN

## Key facts

- **NCT ID:** NCT03997929
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-20
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-02-07
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03997929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03997929, "Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03997929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*